Table 4. Heterogeneity testing of myocardial infarction (exposure) and plasma metabolites (outcome).
| Exposures | Outcome ID | Outcome traits | Method | Cochran’s Q test | P-value |
| MR: Mendelian randomization. | |||||
| Myocardial infarction | GCST90199705 | Propionylglycine levels | MR-Egger | 52.343 | 0.967 |
| Propionylglycine levels | Inverse variance weighted | 52.355 | 0.973 | ||
| Myocardial infarction | GCST90199741 | Gamma-glutamylglycine levels | MR-Egger | 65.633 | 0.717 |
| Gamma-glutamylglycine levels | Inverse variance weighted | 65.707 | 0.743 | ||
| Myocardial infarction | GCST90199807 | Hexadecanedioate (C16-DC) levels | MR-Egger | 77.905 | 0.326 |
| Hexadecanedioate (C16-DC) levels | Inverse variance weighted | 80.242 | 0.289 | ||
| Myocardial infarction | GCST90200054 | 1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4) levels |
MR-Egger | 111.559 | 0.002 |
| 1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4) levels |
Inverse variance weighted | 112.444 | 0.003 | ||
| Myocardial infarction | GCST90200059 | Behenoyl dihydrosphingomyelin (d18:0/22:0) levels |
MR-Egger | 127.943 | < 0.001 |
| Behenoyl dihydrosphingomyelin (d18:0/22:0) levels |
Inverse variance weighted | 138.022 | < 0.001 | ||
| Myocardial infarction | GCST90200065 | 1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6) levels |
MR-Egger | 87.804 | 0.114 |
| 1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6) levels |
Inverse variance weighted | 87.951 | 0.128 | ||
| Myocardial infarction | GCST90200259 | Pentose acid levels | MR-Egger | 79.913 | 0.271 |
| Pentose acid levels | Inverse variance weighted | 81.123 | 0.267 | ||
| Myocardial infarction | GCST90200438 | Alpha-ketobutyrate levels | MR-Egger | 61.234 | 0.835 |
| Alpha-ketobutyrate levels | Inverse variance weighted | 67.340 | 0.694 | ||
| Myocardial infarction | GCST90200630 | X-24546 levels | MR-Egger | 79.854 | 0.273 |
| X-24546 levels | Inverse variance weighted | 83.796 | 0.204 | ||
| Myocardial infarction | GCST90200680 | 5-acetylamino-6-formylamino-3- methyluracil levels |
MR-Egger | 92.405 | 0.006 |
| 5-acetylamino-6-formylamino-3- methyluracil levels |
Inverse variance weighted | 92.425 | 0.007 | ||
| Myocardial infarction | GCST90200707 | Glycine levels | MR-Egger | 71.775 | 0.519 |
| Glycine levels | Inverse variance weighted | 71.813 | 0.550 | ||
| Myocardial infarction | GCST90200726 | N-acetylputrescine to (N (1) + N (8))- acetylspermidine ratio |
MR-Egger | 78.894 | 0.298 |
| N-acetylputrescine to (N (1) + N (8))- acetylspermidine ratio |
Inverse variance weighted | 79.293 | 0.316 | ||
| Myocardial infarction | GCST90200758 | Glycine to serine ratio | MR-Egger | 67.296 | 0.666 |
| Glycine to serine ratio | Inverse variance weighted | 67.315 | 0.696 | ||
| Myocardial infarction | GCST90200782 | Mannose to trans-4-hydroxyproline ratio | MR-Egger | 66.268 | 0.698 |
| Mannose to trans-4-hydroxyproline ratio | Inverse variance weighted | 66.913 | 0.708 | ||